Most HAE is caused by the malfunction of the plasma C1 kallikrein inhibitor protein, and can thus be treated with a substitute kallikrein inhibitor—Ecallantide—during acute HAE attacks (Nussberger et al., 1998). The gene discussed is KLK4; the disease is hereditary angioedema.